Transcenta Holding Limited A Clinical Stage Biopharmaceutical Company With Fully-Integrated Capabilities In Discovery, Research, Development And Manufacturing Of Antibody-Based Therapeutics, Announces That Tst004, Its Best-In-Class, Humanized Monoclonal Antibody Targeting Masp2, Has Received Ind Clearance From U.S. Food And Drug Administration (Fda).Masp2, Mannose-Binding Protein-Associated Serine Protease 2, Is A Key Enzyme In The Lectin Pathway Initiation Of Complement Activation. Studies Have Shown That Lectin Pathway Activation Contributes To Multiple Human Diseases Such As Immunoglobulin A Nephropathy (Igan), Hematopoietic Stem-Cell Transplantation
